Advertisement
Collaboration › Details
Sartorius–Synpromics: genomic technology, 201801 collab existent with Sartorius Stedim Cellca
Period | 2018-01-17 | |
Partner, 1st | Cellca GmbH | |
Today | Sartorius Stedim Cellca GmbH | |
Group | Sartorius (Group) | |
Partner, 2nd | Synpromics Ltd. | |
Group | Bayer (Group) | |
Product | genomic technology | |
Synpromics Ltd.. (1/17/18). "Press Release: Synpromics Appoints Sarah Haecker Meeks, PhD as Vice President of Business Development. Company Establishes U.S. Subsidiary to Expand Operations". Edinburgh.
Synpromics Ltd, the leader in gene control, today announced the appointment of Sarah Haecker Meeks, PhD to the position of Vice President, Business Development. Dr. Haecker Meeks brings a deep expertise in emerging technologies and business strategy focused on the design and development of gene medicines and will lead business development for the company.
“Sarah’s experience is an ideal fit for the Synpromics’ leadership team as we continue to enable therapeutic applications of our synthetic promoter platform,” commented Dr David Venables, Chief Executive Officer of Synpromics Ltd. “She brings the unique combination of deep technical expertise and strategic business acumen optimal for positioning and partnering Synpromics’ platform technology. We’re pleased to have her continue to build upon our nearly 20 current partnerships and support the rapidly expanding use of novel synthetic promoters and gene regulation in gene and cell therapies.”
“I am thrilled to join Synpromics to continue to drive the identification and implementation of new platform applications,” added Sarah Haecker Meeks, “I’m excited about the opportunity to contribute to a company that is poised to revolutionise the way that gene and cell medicines are designed and delivered across multiple therapeutic programmes to advance treatments for numerous diseases.”
Synpromics has also established a new US subsidiary, Synpromics Inc. and Sarah will lead business development activities from the US covering all territories.
Ends
For further information, contact:
Corporate Contact:
Dr David Venables, CEO Synpromics Ltd?
T: +44 (0)7825 323439?
E: David.Venables@synpromics.com
PR Contact:
Deborah Cockerill / Emma Pickup
Sciad Communications Ltd?
T: +44 (0)20 7470 8801?
E: synpromics@sciad.com
Notes to Editors
About Synpromics
Synpromics is the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design. The company has developed PromPT™, its multi-dimensional bioinformatics database that enables product-specific promoter design and selection empowering the next generation of cell and gene based medicines and bioprocessing applications. The company operates in a diverse range of fields, including broad applications in cell and gene based medicine, biologics manufacturing and viral vector bioprocessing. Current partners include Biomarin, uniQure, AGTC, Solid Bio, Homology Medicines, Inc, Adverum, GE Healthcare and Sartorius-Stedim Cellca, as well as numerous undisclosed partners in the pharmaceutical sector.
About Synthetic Promoters
Promoters are the natural switches that control the expression of genes into proteins, and are responsible for decoding the genome. Naturally occurring promoters have evolved for biological functions but have limitations when utilised in industrial or therapeutic applications. Synthetic promoters with DNA sequences not found in nature are designed to better regulate gene activity and precisely control protein production. Synpromics creates highly specific promoters designed to drive gene expression at the desired level and specificity in any cell type, tissue or environmental condition. Each synthetic promoter represents a novel invention and thus can be patented. For more information visit www.synpromics.com
About Dr. Haecker Meeks
Since 2016, Dr. Haecker Meeks has served as a business development consultant for Synpromics. As Chief Scientific Officer at Adjuvant Partners, she led business development and corporate strategy for numerous clients with a focus on cell and gene therapy. She helped found Cardiogen Sciences, Inc. (acquired in 2015 by Audentes Therapeutics) and was the Director, Technology Sections, at the Alliance for Regenerative Medicine managing the Gene Therapy Section and the Genome Editing Task Force. Prior to Adjuvant Partners, Sarah held the position of Vice President, Business Development for Orasi Medical, Circle Biologics and BioE. She earned a Doctorate in molecular biology and bioethics from the University of Minnesota and a Bachelor of Science degree in biochemistry from the University of Wisconsin with continued education at the Wharton School at the University of Pennsylvania. From 1995-2004, she completed a post-doctoral fellowship with James Wilson at the University of Pennsylvania’s Human Gene Therapy Program focused on muscle directed gene therapy as well as having served as a technology licensing manager for the UPENN Center for Technology Transfer.
Record changed: 2023-09-28 |
Advertisement
More documents for Sartorius (Group)
- [1] Refeyn Ltd.. (10/2/23). "Press Release: Refeyn Announces Appointment of New CEO". Oxford....
- [2] Sartorius AG. (9/28/23). "Press Release: Sartorius Forms Partnership with Sparta Biodiscovery on Novel Nanoparticle Analysis Platform". Göttingen....
- [3] Sartorius AG. (8/17/23). "Press Release: Sartorius and Repligen Corporation Launch Integrated System with Biostat STR and XCell ATF for Upstream Process Intensification". Göttingen....
- [4] Helmholtz Zentrum München (Helmholtz Munich). (8/7/23). "Press Release: Life Science Factory to Open a New Location at Helmholtz Munich in 2024". Göttingen & Munich....
- [5] Sartorius AG. (8/3/23). "Press Release: Florian Funck Appointed CFO of Sartorius. New CFO to Take Over as of April 2024". Göttingen....
- [6] Life Science Factory Management GmbH. (7/24/23). "Pressemitteilung: Tatjana Kasper wird neue Geschäftsführerin". Göttingen....
- [7] Waters Corporation. (6/5/23). "Press Release: Waters and Sartorius Expand Collaboration to Deliver Comprehensive Bioanalytics for Downstream Biomanufacturing". Milford, MA & Göttingen....
- [8] va-Q-tec AG. (4/26/23). "Press Release: Sartorius and va-Q-tec Announce a Long-term Partnership for the Joint Development of Innovative Transport Systems for the Biopharmaceutical Industry". Würzburg & Göttingen....
- [9] Sartorius. (3/31/23). "Press Release: Sartorius to Acquire Polyplus. France-based Polyplus Is a Provider of Innovative Upstream Technologies for Cell and Gene Therapies". Göttingen....
- [10] Life Science Valley Ventures Management GmbH. (2/13/23). "Press Release: New Fund for Promoting Life Science Start-ups in Lower Saxony". Göttingen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top